J Cancer 2016; 7(5):512-515. doi:10.7150/jca.13651

Short Research Communication

Loss of MKK3 and MK2 Copy Numbers in Non-Small Cell Lung Cancer

Johanna Samulin Erdem, Vidar Skaug, Aage Haugen, Shanbeh Zienolddiny

Section of Toxicology and Biological Work Environment, Department of Biological and Chemical Work Environment, National Institute of Occupational Health, Oslo, Norway.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Samulin Erdem J, Skaug V, Haugen A, Zienolddiny S. Loss of MKK3 and MK2 Copy Numbers in Non-Small Cell Lung Cancer. J Cancer 2016; 7(5):512-515. doi:10.7150/jca.13651. Available from http://www.jcancer.org/v07p0512.htm

File import instruction


Identification of genetic alterations in members of the p38 mitogen-activated protein kinase (MAPK) pathway is important as these proteins have dynamic roles in tumor progression and may serve as potential therapeutic targets in cancer. We analyzed tumor and non-tumorous lung tissue of 233 non-small cell lung cancer (NSCLC) patients for the presence of copy number alterations (CNAs) in the MAPK kinase 3 (MKK3) and MAPK-activated kinase 2 (MK2) genes. We report frequent CNAs in MKK3 and MK2 genes in NSCLC. Copy number losses were detected in 31% of NSCLC tumors (odds ratio: 7.08, 95% confidence interval: 3.2-15.6, P<0.001) for the MKK3 gene and in 28% of tumors for the MK2 gene (odds ratio: 3.68, 95% confidence interval: 1.9-7.2, P<0.001). Several of the non-tumorous tissues showed an elevated MKK3 copy number, with a concurrent loss of this in 89% of the paired tumors. MKK3 gene deletions were significantly more frequent in squamous and large cell carcinoma than in adenocarcinoma. These data demonstrate a novel loss of MKK3 and MK2 genomic copy numbers in NSCLC tumors, and suggest these genes as interesting therapeutic candidates in NSCLC.

Keywords: MKK3, MK2, p38 MAPK, copy number alterations, non-small cell lung cancer.